Cubist Pharmaceuticals Inc. (CBST)
Keep a close eye on CBST. Reports are on the street indicating that pharmaceutical giant Merck & Co. Inc. (MRK) may acquire the company for more than $7 billion (roughly $100 a share).
For the third quarter 2014, CBST recently reported total net revenues of $309.2 million, increased by 16% year over year, non-GAAP adjusted operating income of $99.1 million compared to $52.5 million in the same period the prior year, and non-GAAP diluted earnings per share of $0.58, versus $0.41 in the third quarter of 2013
CBST is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address significant unmet medical needs in the acute care environment.
More about Cubist Pharmaceuticals Inc. (CBST) at www.cubist.com
**
Crown Equity Holdings Inc. (OTCPK:CRWE)
CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet.
The company is currently developing its CRWE Network ( www.CRWE-PR.com ), a growing network of community targeted sites.
One of the primary goals of the CRWE Network is to offer business owners the power of consumer targeting advertisements on a local and national scale.
CRWE has recently included the City of Sacramento, CA ( www.sacramento.crwe-pr.com ) to the CRWE Network.
Sacramento is the capital city of the U.S. state of California and the seat of government of Sacramento County. It is at the confluence of the Sacramento River and the American River in the northern portion of California's expansive Central Valley.
One of the most historic cities in California, Sacramento boasts an impressive array of landmarks, parks, amenities and other must-see points of interest.
The City of Sacramento had an estimated population in 2013 (U.S. Census Bureau) of approximately 479,686, and represents an important marketplace for the CRWE Network, which business model is based on selling advertising to businesses targeting both locally and nationally
The CRWE Network has reached the 1486th community website in the U.S., associated with 3456 ZIP Codes, and includes coverage in the states of California, Mississippi, Michigan, Florida, Nevada and New York, as well as across 10 provinces in Canada.
The CRWE-PR Business Directory portal ( www.BusinessDirectory.crwe-pr.com ) is the company's business directory service that is available to all United States and Canada business in the public and private sector. It allows business owners and executives the ability to claim their business listings and provide more detailed information for their potential customers who visit the CRWE Network everyday.
CRWE plans to have full national coverage of all U.S and Canada businesses in the future on its CRWE-PR Business Directory, which will be integrated to the CRWE Network.
The CRWE-PR Finance website ( www.finance.crwe-pr.com ) allows CRWE the instant distribution of information to the entire CRWE Network.
Online video is gaining strength as a source for content marketing. Strategic plans are being developed for CRWE's division CRWE Tube ( www.crwetube.com ) to improve the potential future growth for the company.
More about Crown Equity Holdings Inc. (OTCPK:CRWE) at www.crownequityholdings.com
**
Pharmacyclics Inc. (PCYC)
Multiple Myeloma is a blood cancer that most commonly arises from B cells, a type of white blood cell (lymphocyte) that originates in the bone marrow.
When B cells respond to an infection in the body, they normally mature and change into plasma cells.1 If there is only a single malignant plasma cell growth, it is called an isolated (or solitary) plasmacytoma. When there is more than one malignant plasma cell growth, it is known as Multiple Myeloma.
According to the American Cancer Society, an estimated 24,050 Americans will be diagnosed with multiple myeloma in the U.S., and about 11,090 will die from the disease in 2014.
New IMBRUVICA(R) (ibrutinib) Phase II data reported by PCYC suggests that IMBRUVICA demonstrates anti-tumor activity both as a single-agent and as combination therapy in heavily pre-treated patients with relapsed or relapsed/refractory multiple myeloma.
IMBRUVICA, jointly developed and commercialized by PCYC and Janssen Biotech, Inc., is a first-in-class, oral, once-daily therapy that inhibits a protein called Bruton's tyrosine kinase (BTK). BTK is a key signaling molecule in the B-cell receptor signaling complex that plays an important role in the survival and spread of malignant B cells. IMBRUVICA blocks signals that tell malignant B cells to multiply and spread uncontrollably.
PCYC is a biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases.
More about Pharmacyclics Inc. (PCYC) at www.pharmacyclics.com
**
Disclaimer: This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer